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Abstract
The aim of this study was to evaluate the effects of β -1,3-(D)-glucan as an antioxidant and tissue protective agent and study 
the biochemical, histopathologic, and immunohistochemical effects of first therapeutic proteasome inhibitor bortezomib on the 
liver for treating relapsed multiple myeloma. The experiment included 36 adult male rats, which were divided into four treatment 
groups: control (healthy); bortezomib-treated; β-1,3-D-glucan-treated; and bortezomib + β-1,3-(D)-glucan-treated. Each group was 
subdivided into two subgroups based on time of sacrifice (48 or 72 h). After the experiments, superoxide dismutase (SOD) activity 
and lipid peroxidation (LPO) amounts were determined, and immunohistochemical and histopathological changes were examined 
in all rat liver tissues. β -1,3-(D)-Glucan treatment normalized changes of LPO and stimulated an over activity of endogenous SOD. 
The results of the histopathologic parameters showed that treatment with β -1,3-(D)-Glucan in the bortezomib group ameliorated 
the development of non-specific reactive hepatitis (NSRH) and Kupffer cell activation via NF-kB. Administration of β -1,3-(D)-Glucan is 
effective in reversing tissue damage induced by bortezomib in rat livers.
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Sıçanlarda Bortezomib İndüklü Karaciğer Hasarında B-1,3-(D)-
Glukan’ın Hepatoprotektif Etkileri
Özet
Bu çalışmanın amacı, relaps multiple miyelom tedavi etmek için kullanılan ilk terapötik proteazom inhibitörü olan bortezomibin 
karaciğer üzerine immunohistokimyasal, histopatolojik ve biyokimyasal etkilerini araştırmak ve bir antioksidant ve doku koruyucu 
ajan olarak B-1,3-(D)-glukanın etkilerini değerlendirmekdi. Deney; kontrol (sağlıklı), bortezomib ile tedavi, B-1,3-(D)-glukan ile 
tedavi ve bortezomib + B-1,3-(D)-glukan ile tedavi olmak üzere dört tedavi grubuna bölünen 36 yetişkin erkek sıçan içerdi. Her bir 
grup sakrifikasyon zamanına (48 veya 72 saat) göre iki alt gruba ayrıldı. Deneylerin bitiminden sonra, süperoksit dismutaz (SOD) 
aktivitesi ve lipid peroksidasyon (LPO) miktarları ölçüldü ve tüm sıçan karaciğer dokularında immünohistokimyasal ve histopatolojik 
değişiklikler incelendi. B-1,3-(D)-glukan ile tedavi LPO değişikliğini normalize etti ve endojen SOD aktivitesi aşırı uyardı. Histopatolojik 
parametrelerin sonuçları, bortezomib grubunda B-1,3-(D)-glukan ile tedavi NF-kB yoluyla Kupffer hücre aktivasyonunu ve non-spesifik 
reaktif hepatit (NSRH) gelişimini regüle ettiğini gösterdi. B-1,3-(D)-glukan uygulaması, sıçan karaciğerinde bortezomibin neden olduğu 
geri döndürülebilir doku hasarında efektifdir.
Anahtar sözcükler: Bortezomib, β-1,3-(D)-glucan, Oksidatif stress, Karaciğer, Histoloji
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INTRODUCTION
Proteasome is a multicatalytic protein complex and 
the major non-lysosomal system for intracellular protein 
degradation in the eukaryotic cells. Proteasomes work in 
concert with the marking protein ubiquitin and generate 
the ubiquitin-proteasome pathway. This pathway is 
responsible for the controlled degradation of a wide 
range of proteins, including cellular regulators that control 
processes such as the cell cycle, apoptosis, inflammation, 
cell migration, angiogenesis, and transcription [1]. Many 
studies have shown that the proteasome system can act 
as a cellular defense mechanism because it prevents the 
accumulation of aggregation misfolded/oxidized proteins 
generated by post-translational modification errors or 
oxidative stress [2]. 
Bortezomib, a dipeptidyl boronic acid, is the first 
reversible 26S proteasome inhibitor used for the treatment 
of multiple myeloma (MM) in humans [3]. The initial target 
for bortezomib use in MM was the blocking of pathways 
of nuclear factor-kappa B (NF-kB) by limiting proteasomal 
degradation of inhibitor of kappa B alpha (IkBα). Although 
the first studies argued that bortezomib could inhibit 
all pathways of NF-kB, later studies have shown that it 
activates only the canonical pathway in neoplastic cells of 
MM [4]. Bortezomib was also found to be effective on NF-
kB pathways in cancer types other than MM [5]. The drug 
has been shown beneficial in animal-model studies of 
autoimmune diseases such as myasthenia gravis, psoriasis, 
arthritis, and autoimmune encephalomyelitis [6]. 
Therapeutic effectiveness of anti-cancer drugs is 
associated with severe side effects due to their toxicity [7]. 
Bortezomib is one of the more widely used anti-cancer 
drugs for a number of cancers and is metabolized in 
the liver, which can develop drug toxicity due to these 
metabolisms [8]. A few bortezomib-based studies on the 
liver have shown that the 26S ubiquitin-proteasome 
pathway may play an etiologic role in the development 
of liver disorders, especially endoplasmic reticulum 
stress, insulin resistance, alcoholic liver disease, and lipid 
metabolism [9]. Earlier, an experimental study on rates 
revealed that the therapeutic dose of bortezomib and 
its deboronated metabolites M1 and M2 dealkylated to 
form M3 and M4 could causes liver toxicity. This study 
also showed a decrease in cytochrome P450 content 
and activity and an important increase in palmitoyl-CoA 
activity in ex vivo analyses of rat liver samples [10]. However, 
this present research has not found studies about oxidant 
and antioxidant parameters in bortezomib-induced liver 
toxicity. Many studies, though, have demonstrated that 
oxidative stress is responsiple for chemotherapeutic drug-
induced liver toxicology [11]. In mitigation of chemotherapy 
side effects, some antioxidant drugs or agents with anti-
cancer effects have been determined helpful depending 
on the reducing effect on oxidative stress [12]. Many studies 
have shown that beta-1,3-D-glucan, an antioxidant and 
anti-cancer agent, has protective antioxidant activity 
against chemotherapy-induced liver toxicity [13]. 
B-1,3-(D)-Glucanis a long chain polymer of D glucose 
from the cell wall of baker’s yeast (Saccharomyces 
cerevisiae), fungi, and plants. Many experimental studies 
have demonstrated its pharmacological properties, 
especially its immunomodulator, antioxidant, and anti-
tumor effects [14]. The immunomodulator effects of B-1,3-
(D)-Glucan are on innate immune cells andare enlisted for 
immune system reinforcement in humans [15]. B-1,3-(D)-
Glucan acts as an agonist on dectin-1 and complement 
receptor 3 (CR3) on the surface of innate immune cells [16]. 
Recent studies indicate that B-1,3-(D)-Glucan also 
promotes activation of CR3 in granulocytes and destroys 
iC3b-opsonized tumor cells via granulocyte bound-CR3 [17]. 
In addition, B-1,3-(D)-Glucan is a potent antioxidant that 
has been reported to prevent oxidative damage in liver 
and renal ischemia/reperfusion injury [18]. 
This present research aims to determine whether 
an antioxidant such as B-1,3-(D)-Glucan could provide 
a protective effect against bortezomib-induced liver 




The animals were housed in facilities and the 
experiments conducted in accordance with international 
guidelines, and the studies were approved by the 
Institutional Animal Care and Use committee of Ataturk 
University. This study used 36 adult male Sprague-Dawley 
rats (230-250 g) from the Ataturk University Experimental 
Animal Laboratory (ATADEM-Approval No: 2013-03/96). 
Chemicals
Bortezomib (Velcade®) was purchased as a lyophilized 
powder (Velcade; Janssen-Cilag, Beerse, Belgium) and dis-
solved in a sterile saline solution at final concentration. β-1,3- 
D-glucan was purchased from Sigma-Aldrich (Steinheim, 
Germany). All chemicals for laboratory experimentation 
were purchased from Sigma-Aldrich (Germany).
Experimental Design
Four groups (control; bortezomib-treated; β-1,3-D-
glucan-treated; and bortezomib + β-1,3-D-glucan-treated) 
were formed for the research study. Bortezomib, β-1,3-D-
glucan, and bortezomib + β-1,3-D-glucan groups were 
subdivided into two subgroups of six rats each based 
on time of sacrifice: 48 or 72 h after drug administration. 
The rats in the bortezomib and bortezomib + β-1,3-D-
glucan groups were injected subcutaneously (sc) once 
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with 0.2 mg/kg of bortezomib on the first day of the 
study [19]. The rats in the bortezomib group were not 
given any treatment after the bortezomib injection until 
sacrifice. The rats in the bortezomib + β-1,3-D-glucan 
group were injected intraperitoneally (ip) with 75 mg/kg 
of β-1,3-D-glucan every day after bortezomib injection 
until sacrifice. The rats in the β-1,3-D-glucan group were 
injected ip with 75 mg/kg of β-1,3-D-glucan every day 
until sacrifice [13]. 
All six groups were sacrificed with an overdose of a 
general anesthetic (thiopental sodium, 50 mg/kg). The 
livers were then quickly removed from the rats and washed 
in ice-cold saline. Half of the tissues were transferred to a 
biochemistry laboratory and kept at −80°C for biochemical 
analyses, while the other half were fixed in a 10% formalin 
solution for histopathological analyses.
Histopathological Analyses
Preparation of Liver Tissues for Histopathology: The 
livers were fixed in 10% formaldehyde, dehydrated in a 
graded alcohol series, embedded in paraffin wax, and 
sectioned using a Leica RM2125RT microtome (Leica 
Microsystems, Wetzlar, Germany). In this study, 4 μm 
thick sections from paraffin blocks were obtained using 
a systematic randomized sampling method (stereological 
method) for immunohistochemical and histopathologic 
examinations. 
Histopathological Examination of the Liver: Sections 
4-μm thick for histopathological examinations were 
stained with H&E and periodic acid-Schiff (PAS). All livers 
were examined by light microscopy for histopathological 
evaluation of the following parameters: H&E staining 
for sinusoidal expansion; inflammatory cell infiltrates; 
sinusoidal expansion; hyperthrophic degeneration; necrotic 
cell deaths, apoptotic cell deaths.
Biochemical Analyses
Preparation of Liver Tissues for Biochemical Analysis: 
Rat livers were kept at -80°C for biochemical investigation. 
To prepare the tissue homogenates, the liver tissues 
were ground with liquid nitrogen in a mortar, and 0.5 g 
was weighed for each group and treated with 4.5 mL of 
an appropriate buffer. This mixture was homogenized 
on ice using an IKA® Ultra-Turrax homogenizer (IKA 
Labortechnik, Staufen, Germany) for 15 min. Homogenates 
were filtered and centrifuged using a refrigerator 
centrifuge at 4°C. The supernatants were then used to 
determine enzymatic activities. All assays were carried out 
at room temperature. To prepare the tissue homogenates, 
tissues were ground with liquid nitrogen in a mortar. The 
ground tissues (0.5 g each) were then treated with 4.5 mL 
of the appropriate buffer. The mixtures were homogenized 
on ice using an Ultra-Turrax homogenizer for 15 min.
SOD Activity: SOD activity was measured according to 
Sun et al.[20]. The estimation was based on the generation 
of O2− produced by xanthine and xanthine oxidase, which 
react with nitro blue tetrazolium (NTB) to form formazan 
dye. SOD activity was then measured at 560 nm by the 
degree of inhibition of this reaction, and was expressed 
as millimole per minute per milligram of tissue (mmol/
min/mg tissue).
LPO Determination: The level of gastric LPO was 
determined by estimating MDA using the thiobarbituric 
acid test [21]. The rat livers were promptly excised and 
rinsed with cold saline. The livers were weighed and 
homogenized in 10 mL of 100 g/L KCl. The homogenate 
(0.5 mL) was added with a solution containing 0.2 mL 
of 80 g/L sodium laurylsulfate; 1.5 mL of 200 g/L acetic 
acid; 1.5 mL of 8 g/L 2-thiobarbiturate; and 0.3 mL of 
distilled water. The mixture was incubated at 98°C for 1 h. 
Upon cooling, 5 mL of n-Butanol:pyridine (15:l) was added. 
The mixture was vortexed for 1 min and centrifuged for 30 
min at 1875 × g. The absorbance of the supernatant was 
measured at 532 nm. The standard curve was obtained 
by using 1,1,3,3-tetramethoxypropane, and recovery was 
over 90%. The results were expressed as nanomol MDA 
per gram of tissue (nmol/g tissue).
Immunohistochemical Analysis
In addition to the histopathological analyses, activity 
in Kupffer cells was detected by immunohistochemical 
staining of NF-kB protein (p65). Immunohistochemical 
staining for NF-kB protein was performed by an automated 
method on the VENTANA BenchMark GX System (Ventana 
Medical Systems, Inc.) with an ultraView Universal DAB 
Detection Kit on 4-µ sections from a representative block 
in each rat. After deparaffinization to water, the antigenic 
determinant sites for NF-kB were unmasked in citrate 
buffer with steam for 60 min. The primary antibody used for 
NF-kB, an IgG1 class mouse monoclonal directed against 
the p65 (F-6) relA component of the NF-kB complex (Santa 
Cruz sc8008, CA), was used at a dilution of 1:80 for 32 min 
at 37°C. The slides were then incubated with the diluted 
antibody, followed by application of ultraView Universal 
DAB detection kit (Ventana Medical Systems, Inc.). DAB 
was used as a chromogen and hematoxylin as a counter 
stain. Similarly, processed sections from human prostate 
cancer were used as positive controls for p65 (RelA) 
immunostaining, respectively. The specificity of staining 
was confirmed by the inclusion of negative control slides 
processed in the absence of primary antibody on tissue 
from the same animal.
In liver tissue, the numerical density of nuclear 
immunoreactivity for NF-kB of Kupffer cells was evaluated 
according to stereological analyses.In this study, unbiased 
counting frame and fractionator methods to estimate 
numerical density of NF-kB nuclear localization in the 
Kupffer cells were used. Each glass microscope slide was 
sampled using the fractionator principle of the stereology 
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software (Stereo Investigator® version 8.0, Micro Bright-
Field, Colchester, Vermont, USA). NF-kB-positive nuclei 
were counted by using a 63x Leica Plan Apo objective 
(NA = 1.40), which allowed accurate recognition. The 
coefficient of error (CE) for the estimations was the last 
calculated value. The generally accepted highest limit of 
CE is 5% (22). 
Data Analysis
The statistical analysis of all parameters was performed 
by one-way analysis of variance (ANOVA) followed by 
Duncan’s multiple range test (DMRT) using the IBM® SPSS 
software package, version 19.00 (SPSS Inc., Chicago, IL). 
Statistical significance was considered P<0.05. All the 
results were expressed as mean±standard error of the 
mean (SE) for the six rats in each group.
RESULTS
Histopathological Results for Liver Toxicity
All zones (periportal, midzonal, and centrilobular) of 
liver acinus in the control and β-1,3-D-glucan-treated 
groups exhibited a typical appearance (Fig. 1A and B, 
Table 1). Liver tissues in the bortezomib and bortezomib + 
β-1,3-D-glucan-treated groups showed histopathological 
changes, such as cell degeneration, inflammatory cell 
infiltrates and foci, necrotic, and apoptotic cells (Fig. 2A, B, 
C, and D, Table 1). While these histopathological changes 
were at severe level at hour 72 (Fig. 2B and Table 1), they 
were at moderate level at hour 48 in the bortezomib-
treated groups (Fig. 2A and Table 1). Inflammatory cell types 
were generally lymphocytes and macrophages, which 
organized both aggregates (foci) and diffuse, and were 
situated in the all zones of liver acinus (Fig. 2A and B, 
Table 1). Necrotic and degenerative cells (hypertrophic and 
abnormal membrane counters) were dense and focal with 
inflammatory responses. In addition, Councilman bodies 
(apoptotic cell death) and hypertrophic Kupffer cells 
(tissue macrophages) were observed within parenchyma 
in these groups (Fig. 2A and B, Table 1). 
Bortezomib induced these histopathological changes, 
which decreased via β-1,3-D-glucan treatments at both 
hours 48 and 72 (Fig. 2C and D, Table 1). The liver tissues 
Fig 1. The normal appearance of 
organized plates of hepatocytes, 
which are separated by sinusoidal 
capillaries in control group (A) and 
β-1,3-D-glucan group (B); Scale 
bars in A, B, 30 µm
Şekil 1. Kontrol (A) ve β-1,3-D-
glukan (B) grubunda sinüzoidal 
kapillerle ayrılan hepatositlerin or-
ganize kordonların normal görü-
nümleri. A, B ‘deki ölçek barlar, 30 
um
Table 1. Histopathological score for rat liver tissues treated singly and in combination with bortezomib or β-1,3-D-glucan













degeneration - - ++++ ++++ ++ ++
Sinusoidal
expansion - - +++ ++++ + ++
Necrotic cell
deaths - - +++ ++++ + ++
Inflammatory
cell foci or infiltrates - - +++ ++++ - +
Hypertrophic
Kupffer cells - - +++ ++++ - +
- none; + minimal; ++ mild; +++ moderate; ++++ severe
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of the bortezomib + β-1,3-D-glucan-treated group at 
hour 72 had no Councilman bodies, only mild level 
necrotic and degenerative cells within midzonal and 
centrilobular zones, and minimal level inflammatory areas 
(mono and polymorphonuclear leukocytes) within and 
around sinusoids, minimal level hypertrophic Kupffer cells 
(Fig. 2D and Table 1). The bortezomib + β-1,3-D-glucan-
treated group at hour 48 showed no Councilman bodies 
or inflammatory cells and had minimal level necrotic and 
mild level degenerative cells, moderate level binucleate 
hepatocytes within midzonal and centrilobular zones, 
and normal appearance Kupffer cells. The general liver 
histological structures of the Bortezomib + β-1,3-D-
glucan-treated group at hour 48 were close to the control 
group (Fig. 2C and Table 1).
Biochemical Results for Oxidant and 
Antioxidant Parameters
The lipid peroxidation amounts (as indicators of 
oxidative stress of livers) for the treatment and control 
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Fig 2. A- Irregular thickened hepatocyte plates with inflammatory cell infiltrates, Councilman bodies (black 
arrow) and hypertrophic Kupffer cells (white arrows) in parenchyma of livers from bortezomib-treated (hour 
48) group, B- Severe inflammatory cell infiltrates with hepatocytes debris, Councilman bodies (small square) 
in parenchyma of livers from bortezomib-treated (hour 72) group, C- Necrosis in hepatocytes (white arrow) 
and moderate level hypertrophic and binucleate hepatocytes in midzonal and centrilobular zones of the liver 
tissue from bortezomib + β-1,3-D-glucan-treated (hour 48) group, D- Degenerative and binucleate (black 
arrow) hepatocytes and migration and adhesions of inflammatory cells (mono and polymorphonuclear 
leukocytes) within sinusoids in livers from Bortezomib + β-1,3-D-glucan-treated (hour 72) group. Scale bars 
in A, B, C, and D, 30 µm
Şekil 2. A- Bortezomib ile tedavi (saat 48) grubunda karaciğer parankimasında hipertrofik Kupffer hücreleri 
(beyaz oklar), Councilman cisimcikleri (siyah ok) ve inflamatuvar hücre infiltrasyonları ile düzensiz kalınlaşmış 
hepatosit kordonları, B- Bortezomib ile tedavi (saat 72) grubunda karaciğer parankimasında Councilman 
cisimcikleri (küçük kare) ve hepatosit debrisleri ile şiddetli inflamatuvar hücre infiltrasyonları C- Bortezomib+ 
β-1,3-D-glukan (saat 48) ile tedavi grubunun karaciğer dokusunun midzonal ve sentrilobuler bölgelerinde orta 
düzeyde hipertrofik ve iki nükleuslu hepatositler ve hepatositlerde  nekrozis (beyaz ok), D- Bortezomib + β-1,3-
D-glukan (saat 72) ile tedavi grubunun karaciğerlerinde sinüzoidler içinde inflamatuvar hücrelerin (mono ve 
polimorfonükleer lökositler) adhesyonu ve göçü ve dejeneratif ve iki nükleuslu hepatositler (siyah oklar). A, B, 
C ve D ‘deki ölçek barlar, 30 um
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groups are shown in Fig. 3. Hepatic MDA levels in the 
bortezomib treatment groups (hours 48 and 72) with the 
increasing influence of time-dependence was significantly 
higher than the control group (P<0.05). Administration 
of β-1,3-D-glucan significantly reduced the tissue MDA 
levels (26.7%) at hours 48 (25.7%) and 72 in hepatic MDA 
levels increased by bortezomib treatment.
The hepatic SOD enzyme activities for all treatment 
and control groups were measured to understand the 
behavior of the antioxidant defense mechanism and were 
shown in Fig. 4. In both bortezomib treatment groups 
(hours 48 and 72), SOD activity was higher than the 
control group (P<0.05). Administration of β-1,3-D-glucan 
significantly elevated the tissue SOD activity at hours 48 
and 72 in hepatic SOD activity comparing all groups.
Immunohistochemistry Results for p65 (RelA) 
Activity in Kupffer Cells
Kupffer cells are specialized macrophages located in 
the walls of the sinusoids and play an important role in 
late-phase hepatotoxicity. Early-phase hepatic injury-
induced (xenobiotics dependent) Kupffer cells produce 
cytokines and growth factors via canonical NF-κB pathway. 
Activated Kupffer cells increase other inflammatory 
cell migration from the liver microcirculation to the 
parenchyma and lead to hepatic cell death by uncontrolled 
inflammation. NF-κB activation is measured by p65 (NF-κB 
subunit) migration to the nucleus in Kupffer cells. Thus, 
this study investigated the numerical density of nuclear 
p65 localization of Kupffer cells in liver tissues of the 
control and treatment groups using immunohisto-
chemical staining and stereological methods (Fig. 5). The 
numerical density of nuclear p65 (RelA) for treatment and 
control groups are shown in Fig. 6. 
The immunohistochemistry results showed no 
statistically significant differences between the control 
group and β-1,3-D-glucan,Bortezomib + β-1,3-D-glucan 
(hour 48) groups in numerical density of p65, as determined 
by stereological examination of the liver tissues (P>0.05). 
However, this data was high at hour 48 and very high 
at hour 72 after bortezomib treatments (P<0.05). 
Bortezomib treatment-induced increased nuclear p65 
localization was decreased via β-1,3-D-glucan treatments 
at hours 48 and 72 (P<0.05).
DISCUSSION
Hepatotoxicity associated with chemotherapeutic 
agents is of interest to clinicians and researchers. The 
chemotherapeutic agents are among the more commonly 
used drugs associated with hepatotoxic effects ranging 
from acute to chronic damage, hepatitis, steatosis 
Fig 3. Effects of bortezomib, β-1,3-D-glucan, and bortezomib 
+ β-1,3-D-glucan treatments in levels of lipid peroxidation 
(LPO) in rat livers (mean ± S.E.M.) [I; control, II; β-1,3-D-glucan, 
III; bortezomib (hour 48), IV; bortezomib + β-1,3-D-glucan 
(hour 48), V; bortezomib (hour 72), VI; bortezomib + β-1,3-D-
glucan (hour 72)].
Şekil 3. Bortezomib, β-1,3-D-glukan, ve bortezomib + 
β-1,3-D-glukan tedavilerinin sıçan karaciğerlerinde lipid 
peroksidayon (LPO) seviyelerine etkileri (ortalama ± S.E.M.) 
[I; kontrol, II; β-1,3-D-glukan, III; bortezomib (saat 48), IV; 
bortezomib + β-1,3-D-glukan (saat 48), V; bortezomib (saat 
72), VI; bortezomib + β-1,3-D-glukan (saat 72)]
Fig 4. Effects of bortezomib, β-1,3-D-glucan, and bortezomib 
+ β-1,3-D-glucan treatments in activity changes of super-
oxide dismutase (SOD) in rat livers (mean ± S.E.M.) [I; 
control, II; β-1,3-D-glucan, III; bortezomib (hour 48), IV; 
bortezomib+β-1,3-D-glucan (hour 48), V; bortezomib (hour 
72), VI; bortezomib + β-1,3-D-glucan (hour 72)]
Şekil 4. Bortezomib, β-1,3-D-glukan, and bortezomib + β-1,3-
D-glukan tedavilerinin sıçan karaciğerlerinde süperoksit 
dismutaz (SOD) aktivite değişimlerine etkileri (ortalama ± 
S.E.M.) [I; kontrol, II; β-1,3-D-glukan, III; bortezomib (saat 48), 
IV; bortezomib + β-1,3-D-glukan (saat 48), V; bortezomib 
(saat 72), VI; bortezomib + β-1,3-D-glukan (saat 72)]
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cholestasis and granuloma [23]. Bortezomib (PS-341 or 
Velcade®) is a modified dipeptidyl boronic acid 26S 
proteasome inhibitor for the treatment of multiple 
myeloma which is the second most common hematological 
cancer (after non-Hodgkin’s lymphoma) [24]. Although 
Hideshima et al.[25] reported bortezomib is 1.000-times 
more effective for triggering apoptosis on myeloma cells 
than normal plasma cells. There is limited information 
about its effects on other normal cells because of new drug 
marketing. Phase studies have shown that the drug had 
tolerable adverse effects, such as peripheral neuropathy, 
gastrointestinal symptoms, thrombocytopenia, and hypo-
tension in non-target organs [26]. However, a few case 
reports clinically determined that bortezomib increased 
liver enzymes (aspartate aminotransferase, alanine amino-
transferase, and lactate dehydrogenase) levels [27]. 
According to literature, bortezomib-induced hepato-
toxicity has been rarely characterized and or studied. 
This research evaluated the time-dependent histo-
pathological, biochemical, and immunohistochemical 
changes of liver tissues in rats given bortezomib. The 
first observation was that nonspecific reactive hepatitis 
(NSRH) or focal hepatitis was histologically observed in 
the liver tissue of rats given bortezomib alone. NSRH is 
an entity characterized by the presence of Kupffer cell 
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Fig 6. Effects of Bortezomib, β-1,3-D-glucan, and Bortezomib 
+ β-1,3-D-glucan treatments on changes in nuclear p65 
localization in Kupffer cells (mean ± S.E.M.) [I; control, II; β-1,3-
D-glucan, III; bortezomib (hour 48), IV; bortezomib + β-1,3-D-
glucan (hour 48), V; bortezomib (hour 72), VI; bortezomib + 
β-1,3-D-glucan (hour 72)] 
Şekil 6. Bortezomib, β-1,3-D-glukan, and bortezomib + 
β-1,3-D-glukan tedavilerinin sıçan karaciğerlerinde Kupffer 
nüklear p65 lokalizasyon değişimlerine etkileri (ortalama ± 
S.E.M.) [I; kontrol, II; β-1,3-D-glukan, III; bortezomib (saat 48), 
IV; bortezomib + β-1,3-D-glukan (saat 48), V; bortezomib 
(saat 72), VI; bortezomib + β-1,3-D-glukan (saat 72)]
Fig 5. Unbiased counting frames used for numerical calculation of nuclear p65 localization by fractionator method (63×). Nuclear p65 
hitting inclusion lines were calculated [Bortezomib + β-1,3-D-glucan group (hour 48)]
Şekil 5. Parçalama yöntemi (63 ×) tarafından nüklear p65 lokalizasyonu sayısal hesaplaması için kullanılan tarafsız sayım çerçeveleri. 
Dahil hatlara isabet eden nüklear p65 hesaplandı [Bortezomib + β-1,3-D-glukan grubu (saat 48)]
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mobilization, portal inflammatory infiltration, and 
focal periportal necroinflammatory areas (generally 
mononuclear cells) with acidophilic cells (Councilman 
bodies) through the liver parenchyma [28]. Drug-induced 
NSRH is rare and determined in some drugs such as 
naproxen, aspirin, and paclitaxel [29]. This present study is 
the first to report that bortezomib causes drug-induced 
NSRH. According to these findings, liver tissues 48 h after 
bortezomib treatment showed a large number of focal 
necrotic areas with prominent inflammatory responses 
in all zones of the liver acinus. Inflammatory responses 
were associated with the relationship between activated 
(hypertrophic) Kupffer cells and mononuclear cells. 
This study also showed wide sinusoidal expansion and 
hypertrophic changes in hepatocytes in liver parenchyma 
(without focal necroinflammatory areas) in this group. By 
hour 72, bortezomib-treated livers had noticeably greater 
numbers and sizes of focal inflammatory cell infiltrations, 
necrotic areas, and other degenerative changes than 
those observed at 48 hours. 
In summary, this study demonstrated that bortezomib 
treatment-induced prominent liver degeneration was 
apparent by hour 48 and gradually increased until hour 
72. Drug-induced liver toxicity is a common cause of liver 
injury and generally occurs two pathophysiological 
processes. In the first pathway, drugs and their metabolites 
with possible toxic effects directly affect the biochemistry 
of the cell primarily due to increased oxidative stress and 
changes of intracellular signaling pathways associated 
with apoptotic or necrotic cell death in hepatocytes 
(mainly), endothelial cells, and cholangiocytes. In the 
second pathway, these also caused immune response in 
inflammatory cells and triggered cellular damage and 
apoptotic or necrotic cell death in parenchymal cells [30]. 
As a result, these two pathways are related to the 
occurrence of inflammatory and oxidative products in 
the liver [31]. Oxidative stress is often implicated in various 
deleterious processes resulting from an imbalance 
between pro-oxidants (reactive oxygen species [ROS] 
and/or reactive nitrogen species [RNS]) and antioxidants 
in favor of the pro-oxidants [32]. ROS are formed through 
oxidative processes within the cell but can be produced 
at elevated rates under pathophysiological conditions. 
The excessive ROS may attack polyunsaturated fatty acids 
of the cellular membrane and initiate lipid peroxidation 
within the cell, which results in the formation of 
Malondialdehyde (MDA). Malondialdehyde, a reactive 
aldehyde, is the major product of lipid peroxidation 
and widely used to indicate LPO level [33]. Antioxidant 
reactions inhibit the oxidation of cellular compounds via 
antioxidant enzymes and molecules such as SOD, CAT, 
GPx, and GR. SOD is the first line in the defense process 
against superoxide radicals produced by oxidative 
reactions and is a significant parameter to evaluate cellular 
antioxidant activity [34]. In the biochemical analysis the 
terms of SOD and LPO values, this study revealed that 
bortezomib treatment elevated SOD and LPO values 
at hours 48 and 72, increasing with time. However, the 
increase in the LPO values was higher than the increase 
in the SOD values of livers in the bortezomib groups 
compared to other groups. This finding suggested that 
oxidant-antioxidant balance is broken in favor of the 
oxidants in cells, or insufficient levels of antioxidants and 
oxidative stress occur. This elevation is probably related 
to elevated endogenous pro-oxidants associated with 
first pathway and increased exogenous pro-oxidants 
associated with second pathway (resident macrophages 
[Kupffer cells] and infiltrating phagocytes) according to 
this study’s histopathologic findings.
Although bortezomib is a potent apoptotic activator 
via proteasome inhibition, this research showed that it 
caused necrotic (hypertrophic changes) and necrotic cell 
deaths via oxidative stress in focal necroinflammatory 
and other areas in rat livers. In a preclinical in vivo 
toxicity study in rats, an increase in liver enlargement 
(35%) caused by the induction of increased peroxisomal 
acyl-CoA oxidase (60%) activity and after a repeat dose 
of bortezomib was observed [10]. This data overlaps to 
hypertrophic changes of hepatocytes in the present study, 
and increasing LPO amounts may be related to increased 
peroxisomal acyl-CoA oxidase activity and other oxidases 
by induced bortezomib treatments. LPO values above 
vital limits may break down membrane integrity, causing 
necrotic death [35]. In addition, apoptotic cell deaths 
(Councilman bodies) were only observed in the focal 
necroinflammatory areas as well as necrotic cell deaths. 
Apoptotic cell deaths could result from inflammatory 
responses of mononuclear cells [36]. Other than direct 
effects of bortezomib and its metabolites because it 
was only observed in necroinflammatory areas. It was 
shown that Kupffer cells have an important role in the 
initiation and maintenance of this immune response in 
necroinflammatory areas because of the time-dependent 
increase in hypertrophic changes and p65 activity. 
Activated canonical p65 pathway-dependent increased 
proinflammatory cytokine secretion, such as tumour-
necrosis factor (TNF) and interleukin-6 (IL-6) in Kupffer 
cells induces the activation and migration of mono- 
nuclear cells [37,38] toward necroinflammatory areas. 
Furthermore, endothelial cells were shown to have a 
role in endothelial dilatation-dependent this migration. 
In conventional therapies, cancer patients often 
receive complementary medical treatment to prolong 
survival and reduce toxicity in non-target organs. It’s 
necessary that the substances used in complementary 
therapy have protective effects as well as anti-cancer 
properties [39]. β-1,3-D-glucan has been shown in Japanese 
medicine, experimental studies, and clinical trials to 
enhance the effectiveness of chemotherapeutic agents 
on the neoplastic cells and have protective effects on 
non-target organs [40-42]. Therefore, this present experiment 
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examined the effects of β-1,3-D-glucan. Whether β-1,3-
D-glucan had adverse effects on the liver compared 
to the control group was first examined. Delaney et 
al.[43] reported that β-1,3-D-glucan had no toxic effects 
on animals. Similarly, this study did not reveal toxic 
effects in parenchyma or Kupffer cells according to 
immunohistochemical and histopathologic analyses. 
However, LPO values showed an increase in physiological 
levels. Next, this study examined the effectiveness of 
β-1,3-D-glucan as a protective agent against liver damage 
induced by bortezomib. β-1,3-D-glucan significantly 
eliminated bortezomib-induced NSRH findings at both 
48 and 72 hours. However, some histopathologic changes 
were observed in both groups. Diffuse hypertrophic 
hepatocyte degeneration (an irreversible cell damage), 
non-focal necrotic deaths and sinusoidal dilatation were 
observed in the middle-middle, minimal-middle, and 
minimal-middle levels at 48 and 72 hours respectively. 
Hypertrophic Kupffer cells and non-focal inflammatory 
cell infiltrates were also observed at minimal levels at 72 h.
In summary, these findings showed that cellular 
degeneration and inflammatory response were significantly 
decreased in both groups. These findings were also 
parallel with decreasing values of LPO, an important 
indicator of cellular damage and reduced Rel A activity as 
an indicator of inflammatory processes. According to our 
results, β-1,3-D-glucan decreased LPO levels by increasing 
defense mechanisms such as the activity of SOD enzymes. 
This may indicate the presence or trend of increasing 
amounts of superoxide radicals, which could be linked 
with an enhanced SOD activity [44]. Indeed, the increased 
SOD activity would also protect tissues from oxidative 
stress, which reveals that the accumulation of superoxide 
anion radicals might be responsible for an increased 
LPO [45]. Descending necrotic deaths and decreased LPO 
values probably must remain below the threshold value 
required for the activation of Kupffer cells, so it can cause 
an inflammatory response is not generated. In addition, 
β-1,3-D-glucan increased activity on other cellular 
antioxidative enzymes, and its free radical scavenging 
activity [46-49] might contribute to the reduction of oxidative 
stress and cellular degeneration and eliminate NSRH 
findings. In addition, in this group, absence of apoptotic 
death, these deaths did not occur with the direct effect 
of bortezomib and again seems to be associated with the 
inflammatory process.
To knowledge, this present study is the first to show 
that, based on biochemical, immunohistochemical, 
and histopathological findings, the administration of 
bortezomib causes increased tissue damage and NSRH in 
rat livers, and β-1,3-D-glucan may decrease the increasingly 
toxic effects of bortezomib by regulating Kupffer cell 
activation and suppressing oxidative stress leading to 
NSRH. In light of this information, β-1,3-D-glucan may be 
used as a supportive agent for reducing the side effects of 
bortezomib therapy.
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